Wall Street analysts forecast that Aphria Inc (NYSE:APHA) will announce sales of $100.92 million for the current quarter, Zacks reports. Three analysts have issued estimates for Aphria’s earnings, with the highest sales estimate coming in at $104.70 million and the lowest estimate coming in at $95.84 million. Aphria reported sales of $16.58 million in the same quarter last year, which indicates a positive year over year growth rate of 508.7%. The company is expected to issue its next earnings results on Friday, January 10th.
On average, analysts expect that Aphria will report full-year sales of $458.68 million for the current fiscal year, with estimates ranging from $410.27 million to $489.09 million. For the next fiscal year, analysts anticipate that the business will post sales of $628.93 million, with estimates ranging from $451.19 million to $730.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Aphria.
Aphria (NYSE:APHA) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.10. The firm had revenue of $126.10 million for the quarter, compared to analyst estimates of $131.15 million. The company’s revenue was up 848.1% on a year-over-year basis.
Shares of NYSE APHA traded down $0.07 during mid-day trading on Friday, reaching $4.67. The company had a trading volume of 2,770,158 shares, compared to its average volume of 5,297,962. The stock has a market cap of $1.19 billion, a PE ratio of -42.45 and a beta of 2.75. The company has a 50-day moving average price of $4.84 and a two-hundred day moving average price of $6.03. Aphria has a 1-year low of $3.75 and a 1-year high of $10.95.
Several hedge funds and other institutional investors have recently modified their holdings of APHA. Synovus Financial Corp boosted its position in shares of Aphria by 56.9% in the second quarter. Synovus Financial Corp now owns 5,514 shares of the company’s stock worth $39,000 after buying an additional 2,000 shares during the period. Capital Investment Advisory Services LLC boosted its position in shares of Aphria by 2,233.3% in the second quarter. Capital Investment Advisory Services LLC now owns 7,000 shares of the company’s stock worth $43,000 after buying an additional 6,700 shares during the period. Liberty Wealth Management LLC acquired a new stake in shares of Aphria in the second quarter worth $44,000. Tower Research Capital LLC TRC boosted its position in shares of Aphria by 76.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,248 shares of the company’s stock worth $44,000 after buying an additional 2,698 shares during the period. Finally, Lindbrook Capital LLC acquired a new stake in shares of Aphria in the second quarter worth $53,000. Institutional investors and hedge funds own 9.89% of the company’s stock.
Aphria Company Profile
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Featured Article: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.